Business Context and Reporting Period
Nuvation Bio Inc. (NUVB) filed a Current Report on Form 8-K on June 24, 2026, reporting events occurring through June 30, 2026. The filing details the completion of a registered underwritten public offering of convertible senior notes and the concurrent termination of a prior credit agreement.
Key Financial Metrics and Transaction Details
- Debt Issuance: Completed a $250.0 million aggregate principal amount offering of 0.75% Convertible Senior Notes due 2032.
- Over-Allotment Option: Underwriters hold a 30-day option to purchase up to an additional $37.5 million of Notes.
- Net Proceeds: Estimated at approximately $241.2 million (or $277.6 million if the over-allotment is fully exercised), after underwriting discounts and offering expenses.
- Debt Repayment: Used proceeds to fully repay approximately $58.5 million in aggregate obligations (principal, interest, fees, and costs) under a prior Credit Agreement dated March 3, 2025.
- Capped Call Transactions: Entered into transactions costing approximately $14.9 million (or $17.1 million with over-allotment) to reduce potential dilution, with an initial cap price of $10.4580 per share.
- Interest Rate: Notes bear interest at 0.75% per year, payable semiannually beginning January 1, 2027.
- Conversion Terms: Initial conversion price is approximately $7.84 per share (127.4941 shares per $1,000 principal), representing a 35.0% premium to the June 25, 2026 stock price.
Material Changes Versus Prior Period
The filing represents a significant shift in the Company's capital structure. The Company has replaced its existing credit facility with long-term convertible debt. Specifically, the Loan Agreement with Sagard Healthcare Partners, which carried obligations totaling approximately $58.5 million, was terminated and discharged in full on June 30, 2026. This transaction was facilitated by an amendment to the Company's Revenue Interest Financing Agreement to permit the new Notes issuance.
Guidance, Outlook, and Risks
Use of Proceeds: After funding the capped call transactions and repaying the prior credit facility, the Company expects to use remaining net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures.
Redemption and Conversion: The Company may not redeem the Notes prior to July 6, 2029. Holders may convert Notes under specific conditions related to the Company's stock price or upon fundamental changes. In the event of a fundamental change, holders may require the Company to repurchase the Notes at 100% of principal plus accrued interest.
Risks and Contingencies: The filing includes standard forward-looking statements regarding the use of proceeds and market conditions. The Indenture outlines customary events of default, including payment defaults, failure to convert, and bankruptcy events. The Company notes that forward-looking statements are subject to risks described in its SEC filings, particularly the "Risk Factors" section of its Form 10-Q for the quarter ended March 31, 2026.
Investor Verification Checklist
- Verify the final exercise of the underwriters' $37.5 million over-allotment option to confirm total net proceeds.
- Review the full text of the Base Indenture (Exhibit 4.1) and Supplemental Indenture (Exhibit 4.2) for specific conversion adjustment mechanisms and redemption limitations.
- Confirm the terms of the Capped Call Transactions (Exhibit 10.2) to understand the dilution protection cap price of $10.4580.
- Monitor the Company's cash position post-transaction to assess liquidity for general corporate purposes.
- Check subsequent filings for any updates on the Revenue Interest Financing Agreement amendment (Exhibit 10.1).